The tumor microenvironment and immune responses in prostate cancer patients

por Kwon, J T W, Bryant, R J, Parkes, E E
Publicado 2021

Changes in circulating microRNA levels associated with prostate cancer

por Bryant, R J, Pawlowski, T, Catto, J W F, Marsden, G, Vessella, R L, Rhees, B, Kuslich, C, Visakorpi, T, Hamdy, F C
Publicado 2012

The drebrin/EB3 pathway drives invasive activity in prostate cancer

por Dart, A E, Worth, D C, Muir, G, Chandra, A, Morris, J D, McKee, C, Verrill, C, Bryant, R J, Gordon-Weeks, P R
Publicado 2017

Nuclear iASPP may facilitate prostate cancer progression

por Morris, E V, Cerundolo, L, Lu, M, Verrill, C, Fritzsche, F, White, M J, Thalmann, G N, ten Donkelaar, C S, Ratnayaka, I, Salter, V, Hamdy, F C, Lu, X, Bryant, R J
Publicado 2014

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer

por Fletcher, C. E., Deng, L., Orafidiya, F., Yuan, W., Lorentzen, M. P. G. S., Cyran, O. W., Varela-Carver, A., Constantin, T. A., Leach, D. A., Dobbs, F. M., Figueiredo, I., Gurel, B., Parkes, E., Bogdan, D., Pereira, R. R., Zhao, S. G., Neeb, A., Issa, F., Hester, J., Kudo, H., Liu, Y., Philippou, Y., Bristow, R., Knudsen, K., Bryant, R. J., Feng, F. Y., Reed, S. H., Mills, I. G., de Bono, J., Bevan, C. L.
Publicado 2022